

Halina Bartosik-Psujek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3765180/publications.pdf>

Version: 2024-02-01

77
papers

1,130
citations

430874

18
h-index

434195

31
g-index

79
all docs

79
docs citations

79
times ranked

1799
citing authors

#	ARTICLE	IF	CITATIONS
1	Selected factors determining the failure to undertake physical activity in patients with multiple sclerosis in Poland. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 2.	0.9	0
2	Spectral signature of multiple sclerosis. Preliminary studies of blood fraction by ATR FTIR technique. <i>Biochemical and Biophysical Research Communications</i> , 2022, 593, 40-45.	2.1	8
3	The Big Five Personality Traits and Positive Orientation in Polish Adults with Multiple Sclerosis: The Role of Meaning in Life. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5426.	2.6	3
4	Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. <i>Vaccines</i> , 2022, 10, 763.	4.4	7
5	Effects of Robotic Exoskeleton-Aided Gait Training in the Strength, Body Balance, and Walking Speed in Individuals With Multiple Sclerosis: A Single-Group Preliminary Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 175-184.	0.9	8
6	COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 8-11.	1.2	15
7	Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis—A systematic review and network meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102769.	2.0	9
8	Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience. <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 212-222.	1.2	24
9	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland. <i>Journal of Clinical Medicine</i> , 2021, 10, 5225.	2.4	9
10	Acute ischemic stroke in a third trimester of pregnancy — cesarean section followed by mechanical thrombectomy. <i>International Journal of Neuroscience</i> , 2020, 130, 739-742.	1.6	3
11	LHON-MS - The overlaps in clinical and molecular features of both LHON and MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102322.	2.0	1
12	Superficial siderosis and intracranial hypotension syndrome following brachial plexus avulsion injury. A case of surgical treatment. <i>Clinical Neurology and Neurosurgery</i> , 2020, 192, 105723.	1.4	3
13	Fasting Hyperglycemia and Long-term Outcome in Patients with Acute Ischemic Stroke Treated with Mechanical Thrombectomy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104774.	1.6	15
14	Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102071.	2.0	6
15	Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-7.	4.0	5
16	Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland. <i>Neurologia I Neurochirurgia Polska</i> , 2020, 54, 161-168.	1.2	7
17	Safety and tolerability of therapeutic plasma exchange in autoimmune neurological diseases — a retrospective single-centre analysis. <i>Neurologia I Neurochirurgia Polska</i> , 2020, 54, 344-349.	1.2	3
18	Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. <i>Neurologia I Neurochirurgia Polska</i> , 2020, 54, 410-415.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Leczenie i postępowanie objawowe w stwardnieniu rozсіяnym Rekomendacje Sekcji SM i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. , 2020, 15, 191-217.	0.1	4
20	Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. Polish Journal of Radiology, 2020, 85, 272-276.	0.9	0
21	Recommendations for neurological, obstetrical and gynaecological care in women with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurologia I Neurochirurgia Polska, 2020, 54, 125-137.	1.2	2
22	Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis. Clinical Neurology and Neurosurgery, 2019, 184, 105453.	1.4	3
23	Primary diffuse meningeal melanomatosis – a rare form of meningeal melanoma: case report. BMC Neurology, 2019, 19, 271.	1.8	13
24	The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population. PLoS ONE, 2019, 14, e0223863.	2.5	6
25	Profile of Polish patients with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 33-38.	2.0	4
26	FTIR Spectroscopy of Cerebrospinal Fluid Reveals Variations in the Lipid: Protein Ratio at Different Stages of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2019, 68, 281-293.	2.6	14
27	Mild hyponatremia discovered within the first 24 hours of ischemic stroke is a risk factor for early post stroke mortality. Advances in Clinical and Experimental Medicine, 2019, 28, 1321-1327.	1.4	5
28	Internet Usage by Polish Patients With Multiple Sclerosis: A Multicenter Questionnaire Study. Interactive Journal of Medical Research, 2019, 8, e11146.	1.4	4
29	Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients. Neurologia I Neurochirurgia Polska, 2019, 53, 131-137.	1.2	1
30	Vitamin D as an immune modulator in multiple sclerosis. Neurologia I Neurochirurgia Polska, 2019, 53, 113-122.	1.2	14
31	Genetic risk factors of Alzheimer’s disease. European Journal of Clinical and Experimental Medicine, 2019, 17, 57-66.	0.1	0
32	Mechanical thrombectomy: Determining the proportion of eligible acute ischemic stroke patients in the cohort of single academic stroke center. Neurologia I Neurochirurgia Polska, 2018, 52, 359-363.	1.2	5
33	Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Multiple Sclerosis and Related Disorders, 2018, 26, 204-206.	2.0	13
34	The use of immunomodulatory therapy in pregnant patients with multiple sclerosis. Aktualnosci Neurologiczne, 2018, 18, 123-131.	0.1	0
35	Mechanical thrombectomy in acute stroke – Five years of experience in Poland. Neurologia I Neurochirurgia Polska, 2017, 51, 339-346.	1.2	11
36	Single-center experience of stent retriever thrombectomy in acute ischemic stroke. Neurologia I Neurochirurgia Polska, 2017, 51, 12-18.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Processes of plasma protein N-homocysteinylation in multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 709-715.	1.6	8
38	The most important psychological and psychosocial needs of Polish multiple sclerosis patients and their significant others. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1817-1824.	2.2	5
39	Month of birth and level of insolation as risk factors for multiple sclerosis in Poland. <i>PLoS ONE</i> , 2017, 12, e0175156.	2.5	3
40	Intravascular lymphoma mimicking multiple sclerosis. <i>Neurologia I Neurochirurgia Polska</i> , 2016, 50, 313-317.	1.2	3
41	Worse Neurological State During Acute Ischemic Stroke is Associated with a Decrease in Serum Albumin Levels. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 493-496.	2.3	10
42	Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2016, 11, e0157950.	2.5	5
43	Can CRP affect the blood-brain barrier during acute ischemic stroke?. <i>Zdrowie Publiczne</i> , 2015, 125, 99-102.	0.1	0
44	Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study. <i>Central-European Journal of Immunology</i> , 2015, 3, 354-359.	1.2	21
45	New outlook for the treatment of secondary progressive multiple sclerosis. <i>Aktualnosci Neurologiczne</i> , 2015, 15, 130-134.	0.1	0
46	Disappearance of white matter lesions on MRI and clinical recovery after initiating antiretroviral therapy in a case of HIV infection presenting as spastic paraparesis. <i>Neurologia I Neurochirurgia Polska</i> , 2014, 48, 378-381.	1.2	1
47	Quality of life in Polish patients with multiple sclerosis. <i>Advances in Medical Sciences</i> , 2014, 59, 34-38.	2.1	11
48	Pregnancy and childbirth in women with multiple sclerosis. <i>Aktualnosci Neurologiczne</i> , 2014, 14, 25-29.	0.1	0
49	Current model of immunopathogenesis of multiple sclerosis – new therapeutic options. <i>Aktualnosci Neurologiczne</i> , 2014, 14, 117-123.	0.1	0
50	Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. <i>Acta Neurologica Scandinavica</i> , 2013, 127, e33-e36.	2.1	5
51	Neuroborreliosis. <i>Reumatologia</i> , 2013, 1, 63-67.	1.1	1
52	Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. <i>Uppsala Journal of Medical Sciences</i> , 2012, 117, 284-292.	0.9	30
53	Validation analysis of the Polish version of the Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL). <i>Neurologia I Neurochirurgia Polska</i> , 2011, 45, 235-244.	1.2	12
54	CT volume/density ratio as the marker of ischaemic brain injury. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 310-315.	2.1	2

#	ARTICLE	IF	CITATIONS
55	Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 252-256.	2.1	43
56	CSF and serum total-tau and phospho-tau(181P) in MS patients. <i>Open Medicine (Poland)</i> , 2011, 6, 193-200.	1.3	0
57	Does Serum Tau Protein Predict the Outcome of Patients with Ischemic Stroke?. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 241-245.	2.3	56
58	Immunomodulatory Effects of IFN- $\hat{1}^2$ and Lovastatin on Immunophenotype of Monocyte-Derived Dendritic Cells in Multiple Sclerosis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 313-319.	2.3	12
59	Impact of cladribine on soluble adhesion molecules in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 409-413.	2.1	22
60	Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1513-1516.	3.0	36
61	Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. <i>Neurologia I Neurochirurgia Polska</i> , 2010, 44, 443-452.	1.2	22
62	Matrix metalloproteinase-9 contributes to the increase of tau protein in serum during acute ischemic stroke. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 997-999.	1.5	19
63	Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. <i>Pharmacological Reports</i> , 2010, 62, 751-756.	3.3	48
64	SERUM BILIRUBIN AND URIC ACID LEVELS AS THE BAD PROGNOSTIC FACTORS IN THE ISCHEMIC STROKE. <i>International Journal of Neuroscience</i> , 2009, 119, 2243-2249.	1.6	24
65	Paraoxonase 1 activity in different types of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 399-402.	3.0	45
66	B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients – Preliminary study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 676-678.	1.4	4
67	The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 644-647.	1.4	25
68	The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. <i>Journal of Neural Transmission</i> , 2006, 113, 339-345.	2.8	40
69	The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. <i>European Journal of Neurology</i> , 2005, 12, 49-54.	3.3	90
70	Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. <i>Journal of Neural Transmission</i> , 2005, 112, 797-803.	2.8	27
71	Steroid Therapy Altered Serum Levels of CCL2 and CCL5 Chemokines in Multiple Sclerosis Patients during Relapse. <i>European Neurology</i> , 2004, 52, 237-241.	1.4	14
72	Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 390-392.	2.1	54

#	ARTICLE	IF	CITATIONS
73	Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. <i>Journal of Neurology</i> , 2004, 251, 414-420.	3.6	65
74	Markers of inflammation in cerebral ischemia. <i>Neurological Sciences</i> , 2003, 24, 279-280.	1.9	31
75	Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. <i>Neuroscience Letters</i> , 2002, 331, 63-65.	2.1	87
76	Biochemical markers of damage of the central nervous system in multiple sclerosis. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina</i> , 2001, 56, 389-92.	0.0	6
77	A case of the Roussy-Levy syndrome family. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina</i> , 2001, 56, 393-5.	0.0	0